1. Interaction between SCP3 and JAB1 Confers Cancer Therapeutic Resistance and Stem-like Properties through EGF Expression
- Author
-
Kwon-Ho Song, Se Jin Oh, Tae Woo Kim, and Kyung Hee Noh
- Subjects
Uterine Cervical Neoplasms ,Cell Cycle Proteins ,synaptonemal complex protein 3 (SCP3) ,epidermal growth factor (EGF) ,Transcription (biology) ,Tumor Cells, Cultured ,Transcriptional regulation ,Phosphorylation ,Biology (General) ,immune resistance ,Spectroscopy ,Chemistry ,Intracellular Signaling Peptides and Proteins ,General Medicine ,Jun activation domain-binding protein 1 (JAB1) ,Phenotype ,epidermal growth factor receptor (EGFR) ,Computer Science Applications ,Cell biology ,DNA-Binding Proteins ,ErbB Receptors ,Neoplastic Stem Cells ,Female ,Signal Transduction ,QH301-705.5 ,Synaptonemal complex protein 3 ,Article ,Catalysis ,cancer stem cell (CSC) ,Inorganic Chemistry ,chemo-resistance ,Cancer stem cell ,medicine ,Humans ,cancer ,Protein Interaction Domains and Motifs ,Physical and Theoretical Chemistry ,Molecular Biology ,Protein kinase B ,QD1-999 ,Epidermal Growth Factor ,COP9 Signalosome Complex ,Akt/PKB signaling pathway ,AKT ,Organic Chemistry ,Cancer ,medicine.disease ,Drug Resistance, Neoplasm ,Mutation ,Peptide Hydrolases - Abstract
Synaptonemal complex protein 3 (SCP3), a member of the Cor1 family, has been implicated in cancer progression, and therapeutic resistance, as well as cancer stem cell (CSC)-like properties. Previously, we demonstrated that SCP3 promotes these aggressive phenotypes via hyperactivation of the AKT signaling pathway, however, the underlying mechanisms responsible for SCP3-induced AKT activation remain to be elucidated. In this study, we demonstrated that the EGF-EGFR axis is the primary route through which SCP3 acts to activate AKT signaling. SCP3 triggers the EGFR-AKT pathway through transcriptional activation of EGF. Notably, neutralization of secreted EGF by its specific monoclonal antibody reversed SCP3-mediated aggressive phenotypes with a concomitant reversal of EGFR-AKT activation. In an effort to elucidate the molecular mechanisms underlying SCP3-induced transcriptional activation of EGF, we identified Jun activation domain-binding protein 1 (JAB1) as a binding partner of SCP3 using a yeast two-hybrid (Y2H) assay system, and we demonstrated that SCP3 induces EGF transcription through physical interaction with JAB1. Thus, our findings establish a firm molecular link among SCP3, EGFR, and AKT by identifying the novel roles of SCP3 in transcriptional regulation. We believe that these findings hold important implications for controlling SCP3high therapeutic-refractory cancer.
- Published
- 2021